Federal Register Notice: FDA’s Anti-Infective Drugs Advisory Committee will meet 1/22/15, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss Astellas Pharma NDAs 207-500 and 207-501, isavuconazonium sulfate capsules and isavuconazonium sulfate for injection for the proposed indications of treatment of invasive aspergillosis and mucormycosis. Contact Jennifer Shepherd, (301) 796-9001. To view this notice, click here.